Acer Therapeutics — Opexa Therapeutics — Investor Presentation (September 2014)
27 slides from Acer Therapeutics's investor presentation, Sep 8, 2014
Slide 1: Opexa Therapeutics: Precision Immunotherapy
Opexa Therapeutics, Inc. NASDAQ: OPXA Precision Immunotherapy September 2014 The Woodlands, TX Precision Immunotherapy TM
Slide 2: Forward-Looking Statements
2 Forward-Looking Statements All statements in this presentation other than those of historical fact,including statements regarding our preclinical and clinical development plans for Tcelna® and OPX 212, our research and other development programs, our ability to undertake certain activities and acc
Slide 3: Opexa Key Investment Highlights
3 Opexa Key Investment Highlights • Personalized T-cell immunotherapy platform – Autologous cell therapy – Potential to address multiple therapeutic areas – Strong Patent Estate: 50 patents issued on T-cell platform (domestic and international) • Lead Indication: Multiple Sclerosis – Ongoing Phase 2
Slide 4: Developing Highly Differentiated, Precision Therapies
4 Opexa Developing Highly Differentiated, Precision Therapies OPX-212 Preclinical Phase 1 Phase 2 Phase 3 Programs and indications Neuromyelitis Optica (NMO) IND enabling studies ongoing in 2H 2014 Tcelna (imilecleucel-T) * Relapsing Remitting Multiple Sclerosis (RRMS) Phase 3 not initiated *Option
Slide 5: Recent and Upcoming Expected Milestones
5 Recent and Upcoming Expected Milestones 1H 2014: Completed Enrollment in Phase 2b SPMS trial 1H 2014: Initiated Early Development Plan for second indication (NMO)• 2H 2014: Advance Preclinical Development in NMO• Mid- 2015: Submit IND for OPX-212 in NMO to FDA• 2H 2015: Initiation of Clinical Deve
Slide 6: Tcelna (imilecleucel-T) Multiple Sclerosis
TCELNA® (imilecleucel-T) MULTIPLE SCLEROSIS 6
Slide 7: Tcelna Lead Program Targeting Secondary Progressive MS
7 Tcelna®Lead Program Targeting Secondary Progressive MS patientsFast Track Designation by FDA • Phase 2b clinical trial ongoing• Trial is fully enrolled: 190 patients with SPMS• Top line data expected in 2H 2016• Design– Double-blind, 1:1 randomized, placebo-controlled– 35 clinical sites in USA and
Slide 8: The Root Cause of Multiple Sclerosis: Activated T-cells Degrade Myelin
8 The Root Cause of Multiple Sclerosis: Activated T- cells Degrade Myelin and Damage Myelin Producing CellsAdapted by permission from Macmillan Publishers Ltd: NATURE REVIEWS IMMUNOLOGY 3, 483-492 (June 2003), copyright (2003) Cytokines Damage Damage• In MS patients, the faulty immune system is not
Slide 9: Differentiation of Tcelna in SPMS
9 Differentiation of Tcelna in SPMS SPMS $7 billion? RRMS $13 billion ?* glatiramer acetate Novantrone Blood Brain Barrier sealed natalizumab Betainterferon teriflunomide X Safe and well tolerated siponimod * Subject to successful clinical development and FDA approval X Lack of efficacy demonstrated
Slide 10: Merck Serono Agreement
10 Merck Serono Agreement signed 2013; strong potential partner Option and License Agreement for worldwide rights to all Multiple Sclerosis indications, excluding Japan • If Merck Serono exercises option: – Merck Serono to fund Phase 3, pre-commercial and commercial activities – Merck Serono obtains
Slide 11: ImmPath: Proprietary Drug Development Platform
(Gp orexa IMMPATH® : PROPRIETARY DRUG DEVELOPMENT PLATFORM
Slide 12: Proprietary Platform and ImmPath Manufacturing Process
‘ee OPEXA THER ics Proprietary Platform Leverage existing platform to generate new drug candidates ImmPath® Manufacturing Process Predecessors to Manufacturing, | Manufacturing |iDispensation - ‘T-cell expansion Final Patient Centralized a —». Procurement —» a (drug, \—»| Formulation | Drug Shipment
Slide 13: OPX-212: Neuromyelitis Optica (NMO)
‘se OPEXA OPX-212: NEUROMYELITIS OPTICA (NMO)
Slide 14: Comprehensive Process to Determine Optimal Additional Indications
Comprehensive Process to Determine Optimal Additional Indications for Opexa Potential Disease Targets off Platform “_ | Addison’s disease Evaluation Criteria Autoimmune hemolytic anemia | Azospermia Celiac Disease Short List of ‘Goodpasture’s syndrome Diseases Grave's Disease Hashimoto's thyroiditis
Slide 15: Neuromyelitis Optica (NMO) Market Opportunity
‘oe OPEXA THERAPEUTICS Neuromyelitis Optica (NMO) Market Opportunity NMOis a rare inflammatory demyelinating disease of the CNS. . . . i t sy ot ~< Epidemiological Affects any age varying from 3 to 90 years, the average age of onset ~41 years Trend d 1-2 people per 100, U.S.: 4,800, EU: 5,800, Japan
Slide 16: Disease Pathogenesis
a * GB) over tswareurics Disease Pathogenesis An astrocytopathic disease of the CNS characterized by optic neuritis, transverse myelitis; it is a B-cell-dependent disease associated with anti-aquaporin-4 antibodies hogs Inflamm: Plasma Cell em me CD4+ T-cell CD69. Inyltration of “ macrophages and Be
Slide 17: Potential Intervention Points for T-cell Therapy
‘ee OPEXA THERAPEUTICS Potential Intervention Points for T-cell Therapy T-cell therapy believed to inhibit AQP-4 autoantibody, pro-inflammatory cytokines and prevent infiltration of macrophages and granulocytes Plasma Nal —_— [opx-21 | PS OPX-212 expected to down. regulate pathogenic AQP-4 T-cells J
Slide 18: NMO Development Program
NMO Development Program OPX-212 Early Development Plan was initiated in Q1 2014 ‘ompleted Aci S Regulatory/Clinical = Pre-IND meeting conducted with FDA V_ Qi220%4 | Engaged Thought Leaders - Engaged Patient Advocacy Groups R&D, Process Development, Manufacturing - Scientific justification of Mechan
Slide 19: Clinical Data
( 3) OPEXA CLINICAL DATA
Slide 20: Tcelna Development Program
Tcelna Development Program Broad Spectrum of Multiple Sclerosis patients enrolled in clinical trials Completion Total eatment Bhase Dates N Duration elna_ | Placebo (months) RRMS, PPMS, Up to 24 BES 1998) SPMS (26) a months a Phase I dose RRMS (5) escalation eco SPMS (6) a6 2 © - Phase I/II RRMS (9)
Slide 21: Phase 2b RRMS clinical trial
Phase 2b RRMS clinical trial Tcelna showed 37% improvement over placebo (mITT) 37% Reduction in Annualized Relapse Rate (ARR) * Tcelna Placebo g $ > e > 5 3 3 a & a g a a} o 7 n=94 Total mITT
Slide 22: Phase 2b RRMS Clinical Trial: Sub-population
@®@ ovexa tHewsvevrics Phase 2b RRMS Clinical Trial Sub-population of patients (n=50) with more progressed/active disease profile (baseline ARR >1) Annualized Relapse Rate (ARR) at Week 52 Change in Disability (EDSS) at Week 52 (=0.045) =eTcelna Placebo 55% Reduction in
Slide 23: Phase I/II SPMS Clinical Trials
Phase I/II SPMS Clinical Trials Tcelna Stabilizes Disease in SPMS at 2 Years 80% of patients showed no further disease progression by EDSS at 2 years Stabilization vs. Historical Progression * Stable Progressed 9 3 g 5 2 a e) Bq os 25 Qs ers 28 ie va) a ° o $ ie 5 a Tcelna Open Label Historical Dise
Slide 24: Financials
Financials (GB orexa Cash and Cash Equivalents (MM) as of June 30, 2014 Shares outstanding (MM) as of June 30, 2014 Warrants (MM) (1) Stock Options (MM) (2) Debt (1) Weighted average exercise price =$4.12 as of June 30, 2014 (2) Weighted average exercise price = $2.96 as of June 30, 2014 None
Slide 25: Experienced Management Team and Board of Directors
@ overs wieravevncs Experienced Management Team and Board of Directors Neil Warma, President & CEO, Director > 19+ years international healthcare experience with large Pharma and emerging, biotechnology companies Board of Directors rothy Barabe, > Former Senior Novartis icals, Basel, > Former CEO, V
Slide 26: SPMS Scientific Advisory Board
BD ovexa SPMS Scientific Advisory Board > Dawn McGuire, M.D., FAAN (Chair) + Advisory Council of the Gill Heart Institute + Former Vice President of Clinical Research at Elan Pharmaceuticals Hans-Peter Hartung, M.D + Chair of Neurology at Heinrich-Heine University, Diisseldorf + Executive Board memb
Slide 27: Investment Thesis
@ ov Investment Thesis TECHNOLOGY * Proprietary Platform: potential to yield multiple drug candidates * Differentiated, personalized approach + Strong patent estate (over 50 domestic and international) PIPELINE * Tcelna: Secondary Progressive MS, limited competition, $7BN potential market * OPX-212:
Opexa Therapeutics — Investor Presentation (September 2014) on 6ix